EyePoint completes enrollment in Phase 3 DURAVYU diabetic macular edema trials COMO, CAPRI - EYPT News | RalliesEyePoint completes enrollment in Phase 3 DURAVYU diabetic macular edema trials COMO, CAPRI
E
EYPT• Phase 3 enrollment completed for DURAVYU in diabetic macular edema
- EyePoint completed enrollment in two Phase 3 trials of DURAVYU for diabetic macular edema, enrolling over 480 patients in five months.
- Topline 56-week results have not been presented; the readout is expected in 4Q 2027.
- The studies aim to show DURAVYU can match standard care while reducing how often patients need treatment.
- A safety committee review in May 2026 supported continuing the Phase 3 programs without changes.
•
